Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CK-3773274 - Granules in Capsule
CK-3773274- Granules · 1 trial · 2 indications
Subject incidence of AEs, SAEs, and reduced LVEF
| Arm | Type | Description |
|---|---|---|
| CK-3773274 for SAD Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274 |
| Placebo for SAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo |
| CK-3773274 for MAD Cohorts | EXPERIMENTAL | Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274 |
| Placebo for MAD Cohorts | PLACEBO_COMPARATOR | Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo |
| CK-3773274 for CYP2D6 Cohort | EXPERIMENTAL | Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274 |
| Placebo for CYP2D6 Cohort | PLACEBO_COMPARATOR | Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo |
| Food Effect | EXPERIMENTAL | Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion |
| Relative Bioavailability | EXPERIMENTAL | Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion. |
| Name | Type | Description |
|---|---|---|
| CK-3773274 - Granules in Capsule | DRUG | CK-3773274 formulated as granules in capsule |
| Placebo - Granules in Capsule | DRUG | Placebo formulated as granules in capsule |
| CK-3773274 - Tablets | DRUG | CK-3773274 formulated as tablets |
Inclusion Criteria: 1. Males and females (of non-childbearing potential) between 18 and 55 years of age, inclusive 2. Body weight \> 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive 3. Normal cardiac structure and function, or if abnormalities are present, they are deemed not clinic...
CK-3773274- Granules in is an investigational small molecule developed by Cytokinetics, Incorporated for symptomatic obstructive hypertrophic cardiomyopathy, a cardiovascular condition. It is also known as CK-3773274 - Granules in Capsule. The drug has completed a Phase 1 clinical trial and has not been approved by the FDA.
CK-3773274- Granules in is being developed for symptomatic obstructive hypertrophic cardiomyopathy, a cardiovascular condition in which the heart muscle thickens and obstructs blood flow. The program is at the Phase 1 stage, so the drug remains investigational and is not yet available as a treatment.
CK-3773274- Granules in is developed by Cytokinetics, Incorporated, which trades on the Nasdaq under the ticker CYTK. The company is the sponsor of the clinical program studying this small molecule in symptomatic obstructive hypertrophic cardiomyopathy.
CK-3773274- Granules in is in Phase 1. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA for any indication.
CK-3773274- Granules in has been studied in NCT03767855, a Phase 1 single and multiple ascending dose trial in healthy adult subjects. The trial enrolled 114 participants, was randomized, double-blind, and placebo-controlled, and was conducted in the United States. It has completed.
Yes, CK-3773274- Granules in and CK-3773274 - Granules in Capsule refer to the same investigational drug from Cytokinetics, Incorporated. The two names describe the same small molecule being studied in symptomatic obstructive hypertrophic cardiomyopathy, so searches for either name point to the same asset.